

# Lars Wallentin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7361887/publications.pdf>

Version: 2024-02-01

254  
papers

44,299  
citations

12597

71  
h-index

2289

206  
g-index

264  
all docs

264  
docs citations

264  
times ranked

31529  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	13.9	9,839
2	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	13.9	7,537
3	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 361, 1045-1057.	13.9	6,019
4	Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden. <i>New England Journal of Medicine</i> , 2007, 356, 1009-1019.	13.9	1,113
5	Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2006, 354, 1464-1476.	13.9	1,104
6	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. <i>Lancet</i> , The, 2017, 389, 1025-1034.	6.3	840
7	The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2014, 63, 321-328.	1.2	733
8	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , 2019, 51, 957-972.	9.4	549
9	The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). <i>Heart</i> , 2010, 96, 1617-1621.	1.2	537
10	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1702-1711.	13.9	467
11	Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. <i>European Heart Journal</i> , 2007, 29, 21-30.	1.0	408
12	Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. <i>American Heart Journal</i> , 2010, 159, 331-339.	1.2	407
13	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neurology</i> , The, 2010, 9, 1157-1163.	4.9	399
14	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet</i> , The, 2016, 387, 2302-2311.	6.3	389
15	Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. <i>Clinical Chemistry</i> , 2017, 63, 140-151.	1.5	380
16	Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2009, 157, 599-605.	1.2	363
17	Association Between Adoption of Evidence-Based Treatment and Survival for Patients With ST-Elevation Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1677.	3.8	356
18	Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2012, 125, 1605-1616.	1.6	346

#	ARTICLE	IF	CITATIONS
19	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1582-1590.	1.0	329
20	Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. <i>Circulation</i> , 2014, 129, 1568-1576.	1.6	324
21	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 1864-1872.	1.0	303
22	Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. <i>European Heart Journal</i> , 2017, 38, 3056-3065.	1.0	302
23	Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. <i>American Heart Journal</i> , 2009, 157, 805-810.e2.	1.2	298
24	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. <i>Nature Genetics</i> , 2018, 50, 26-41.	9.4	286
25	Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK. <i>Lancet, The</i> , 2014, 383, 1305-1312.	6.3	258
26	Biomarkers in atrial fibrillation: a clinical review. <i>European Heart Journal</i> , 2013, 34, 1475-1480.	1.0	246
27	Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 130, 1847-1858.	1.6	243
28	5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. <i>Lancet, The</i> , 2006, 368, 998-1004.	6.3	242
29	Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. <i>New England Journal of Medicine</i> , 2017, 377, 1132-1142.	13.9	228
30	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. <i>Lancet, The</i> , 2016, 388, 1161-1169.	6.3	216
31	Rapid Endovascular Catheter Core Cooling Combined With Cold Saline as an Adjunct to Percutaneous Coronary Intervention for the Treatment of Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1857-1865.	1.2	203
32	Changes in Renal Function in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2481-2493.	1.2	197
33	N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2274-2284.	1.2	191
34	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1689-1700.	1.2	186
35	Inflammatory Biomarkers Interleukin-6 and C-reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of) Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1114-1124.	1.0	175
36	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015, 36, ehv304.	1.0	175

#	ARTICLE	IF	CITATIONS
37	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. <i>European Heart Journal</i> , 2014, 35, 2083-2093.	1.0	171
38	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017, 38, ehw525.	1.0	164
39	Digoxin and Mortality in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1063-1074.	1.2	147
40	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2015, 36, 1264-1272.	1.0	144
41	Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. <i>European Heart Journal</i> , 2016, 37, 3335-3342.	1.0	138
42	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time. <i>JAMA Cardiology</i> , 2016, 1, 451.	3.0	137
43	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. <i>European Heart Journal</i> , 2016, 37, 1325-1333.	1.0	137
44	High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 52-61.	1.2	133
45	The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. <i>European Heart Journal</i> , 2005, 26, 308-313.	1.0	132
46	Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. <i>BMJ</i> , 2016, 353, i2868.	3.0	123
47	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
48	Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. <i>European Heart Journal</i> , 2018, 39, 3766-3776.	1.0	112
49	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T patients with coronary heart disease. <i>American Heart Journal</i> , 2010, 160, 655-661.e2.	1.2	111
50	Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. <i>European Heart Journal</i> , 2018, 39, 1078-1085.	1.0	109
51	GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men. <i>PLoS ONE</i> , 2013, 8, e78797.	1.1	108
52	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. <i>European Heart Journal</i> , 2015, 36, 1901-1912.	1.0	107
53	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	1.0	106
54	Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. <i>European Heart Journal</i> , 2016, 37, 1993-2001.	1.0	101

#	ARTICLE	IF	CITATIONS
55	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. <i>Circulation</i> , 2014, 129, 293-303.	1.6	100
56	Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015, 170, 1151-1160.	1.2	99
57	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. <i>Clinical Chemistry</i> , 2017, 63, 325-333.	1.5	97
58	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 813-826.	1.2	95
59	Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries. <i>BMJ</i> , 2015, 351, h3913.	3.0	94
60	Comparative Efficacy and Safety of Oral P2Y <sub>12</sub> Inhibitors in Acute Coronary Syndrome. <i>Circulation</i> , 2020, 142, 150-160.	1.6	93
61	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, Tj ETQq1 1 0.784314 rrgBT /Overlock 10 T	1.6	92
62	Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2015, 169, 899-905.e1.	1.2	91
63	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 4037-4046.	1.0	90
64	Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution. <i>Nature Genetics</i> , 2019, 51, 452-469.	9.4	89
65	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. <i>Circulation</i> , 2020, 141, 1384-1392.	1.6	87
66	Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1541-1550.	1.2	84
67	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	5.5	84
68	Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 734-742.	0.8	82
69	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. <i>American Journal of Human Genetics</i> , 2016, 99, 40-55.	2.6	82
70	ProteinSeq: High-Performance Proteomic Analyses by Proximity Ligation and Next Generation Sequencing. <i>PLoS ONE</i> , 2011, 6, e25583.	1.1	80
71	Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. <i>Clinical Cardiology</i> , 2019, 42, 568-571.	0.7	80
72	Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation. <i>Clinical Chemistry</i> , 2017, 63, 152-164.	1.5	79

#	ARTICLE	IF	CITATIONS
73	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017, 103, 1015-1023.	1.2	78
74	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 1697-1707.	1.6	76
75	ST2 and mortality in non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , 2010, 159, 788-794.	1.2	71
76	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2014, 35, 1541-1550.	1.0	70
77	All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. <i>Heart</i> , 2016, 102, 926-933.	1.2	70
78	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. <i>PLoS Medicine</i> , 2021, 18, e1003513.	3.9	70
79	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	68
80	Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. <i>Lancet</i> , The, 2016, 388, 1903-1911.	6.3	68
81	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. <i>Heart</i> , 2016, 102, 508-517.	1.2	67
82	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2135-2144.	1.2	66
83	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	1.0	63
84	Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 678-685.	0.8	60
85	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. <i>American Journal of Human Genetics</i> , 2016, 99, 8-21.	2.6	60
86	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 86-94.	1.4	59
87	Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. <i>Journal of Internal Medicine</i> , 2018, 283, 83-92.	2.7	57
88	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2018, 3, 1160.	3.0	57
89	Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. <i>Heart</i> , 2016, 102, 617-625.	1.2	56
90	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 255-267.	1.2	56

#	ARTICLE	IF	CITATIONS
91	EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials. <i>European Heart Journal</i> , 2019, 40, 2745-2749.	1.0	56
92	Therapeutic Hypothermia for the Treatment of Acute Myocardial Infarction—Combined Analysis of the RAPID MI-ICE and the CHILL-MI Trials. <i>Therapeutic Hypothermia and Temperature Management</i> , 2015, 5, 77-84.	0.3	54
93	Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2019, 208, 123-131.	1.2	54
94	Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry. <i>European Heart Journal</i> , 2020, 41, 833-843.	1.0	53
95	European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 4-13.	1.8	52
96	Potent P2Y <sub>12</sub> Inhibitors in Men Versus Women. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1549-1559.	1.2	51
97	Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial. <i>American Heart Journal</i> , 2004, 148, 566-573.	1.2	50
98	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. <i>American Journal of Human Genetics</i> , 2016, 99, 22-39.	2.6	50
99	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 162-171.	1.2	50
100	Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. <i>Heart</i> , 2014, 100, 1193-1200.	1.2	47
101	Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1493-1499.	1.2	47
102	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. <i>European Heart Journal</i> , 2017, 38, 2813-2822.	1.0	45
103	Lipoprotein-associated Phospholipase A <sub>2</sub> Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	44
104	Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. <i>European Heart Journal</i> , 2017, 38, 1048-1055.	1.0	44
105	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 2242-2248.	1.0	42
106	Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. <i>American Heart Journal</i> , 2015, 169, 879-889.e7.	1.2	42
107	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017, 190, 94-103.	1.2	42
108	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , 2021, 99, 926-939.	2.6	42

#	ARTICLE	IF	CITATIONS
109	Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 771-778.	0.8	41
110	New Generation Cardiac Troponin I Assay for the Access Immunoassay System. <i>Clinical Chemistry</i> , 2001, 47, 959-961.	1.5	40
111	Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1048-1057.	1.2	40
112	Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 5-12.	1.4	40
113	Tooth loss is independently associated with poor outcomes in stable coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 839-846.	0.8	39
114	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. <i>Heart</i> , 2014, 100, 1762-1769.	1.2	38
115	Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2016, 202, 589-594.	0.8	38
116	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. <i>Clinical Chemistry</i> , 2015, 61, 368-378.	1.5	37
117	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e002490.	1.6	37
118	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017, 186, 91-99.	1.2	36
119	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESCâ€œORP Heart Failure Longâ€œterm Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	2.9	36
120	Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 671-683.	1.1	35
121	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, ehv447.	1.0	35
122	Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?. <i>American Heart Journal</i> , 2014, 168, 611-621.	1.2	34
123	D-dimer and factor VIIa in atrial fibrillation â€œ prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	1.8	34
124	Dabigatran etexilate and reduction in serum apolipoprotein B. <i>Heart</i> , 2016, 102, 57-62.	1.2	34
125	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 1666-1676.	1.6	34
126	From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1618-1636.	1.2	33



#	ARTICLE	IF	CITATIONS
127	Association Between the Use of Fondaparinux vs Low-Molecular-Weight Heparin and Clinical Outcomes in Patients With Non-“ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2015, 313, 707.	3.8	31
128	Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction—a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). American Heart Journal, 2016, 175, 36-46.	1.2	31
129	Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 72, 721-733.	1.2	31
130	Economic Analysis of Ticagrelor Therapy From a U.S. Perspective. Journal of the American College of Cardiology, 2015, 65, 465-476.	1.2	30
131	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. Thrombosis Research, 2016, 139, 77-81.	0.8	29
132	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. Journal of the American College of Cardiology, 2020, 75, 1145-1155.	1.2	28
133	Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. Journal of the American Heart Association, 2017, 6, .	1.6	27
134	Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study. Thrombosis and Haemostasis, 2020, 120, 412-422.	1.8	27
135	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-“ST-Elevation Acute Coronary Syndrome. Clinical Chemistry, 2017, 63, 573-584.	1.5	26
136	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. American Heart Journal, 2017, 187, 194-203.	1.2	26
137	Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. Journal of Internal Medicine, 2018, 283, 282-292.	2.7	25
138	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 856-864.	1.1	25
139	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. European Heart Journal, 2020, 41, 2848-2859.	1.0	25
140	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. Circulation, 2020, 141, 10-20.	1.6	24
141	Understanding the use of observational and randomized data in cardiovascular medicine. European Heart Journal, 2020, 41, 2571-2578.	1.0	24
142	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal, 2016, 177, 1-8.	1.2	23
143	Magnitude of Troponin Elevation and Long-Term Clinical Outcomes in Acute Coronary Syndrome Patients Treated With and Without Revascularization. Circulation: Cardiovascular Interventions, 2015, 8, e002314.	1.4	22
144	Sudden Cardiac Death After Non-“ST-Segment Elevation Acute Coronary Syndrome. JAMA Cardiology, 2016, 1, 73.	3.0	22

#	ARTICLE	IF	CITATIONS
145	Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by) Tj ETQq1 1 @.784314 zgBT /Over	0.8	22
146	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. <i>International Journal of Cardiology</i> , 2017, 245, 271-276.	0.8	22
147	Vorapaxar with or without clopidogrel after non-â€œST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial. <i>American Heart Journal</i> , 2014, 168, 869-877.e1.	1.2	21
148	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. <i>Pharmacogenomics</i> , 2016, 17, 1425-1439.	0.6	21
149	Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. <i>Stroke</i> , 2017, 48, 3266-3273.	1.0	20
150	Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 294-302.	1.1	20
151	Methodology for the development of international clinical data standards for common cardiovascular conditions: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2023, 9, 161-168.	1.8	20
152	Genetic Landscape of the ACE2 Coronavirus Receptor. <i>Circulation</i> , 2022, 145, 1398-1411.	1.6	20
153	Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes. <i>Journal of the American Heart Association</i> , 2015, 4, e001512.	1.6	19
154	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016, 18, 973-978.	0.7	19
155	Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. <i>Heart</i> , 2019, 105, 235-242.	1.2	19
156	Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease â€œ A STABILITY Substudy. <i>Journal of the American Heart Association</i> , 2022, 11, e023667.	1.6	19
157	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2014, 168, 68-75.e2.	1.2	18
158	Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 145-153.	1.0	18
159	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
160	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2112-2123.	1.8	18
161	Usefulness and Safety of Vorapaxar in Patients With Non-â€œST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014, 114, 665-673.	0.7	17
162	Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-â€œST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014, 113, 936-944.	0.7	17

#	ARTICLE	IF	CITATIONS
163	Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATElet inhibition and patient Outcomes study. <i>American Heart Journal</i> , 2014, 168, 96-102.e2.	1.2	17
164	Evaluation of Temporal Changes in Cardiovascular Biomarker Concentrations Improves Risk Prediction in an Elderly Population from the Community. <i>Clinical Chemistry</i> , 2016, 62, 485-493.	1.5	17
165	Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 500-510.	0.4	17
166	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2726-2737.	1.9	17
167	How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. <i>American Heart Journal</i> , 2014, 168, 622-631.e2.	1.2	16
168	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016, 175, 175-183.	1.2	16
169	Relative efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. <i>Clinical Cardiology</i> , 2017, 40, 390-398.	0.7	16
170	Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. <i>PLoS ONE</i> , 2017, 12, e0182115.	1.1	16
171	Interleukin-18 in patients with acute coronary syndromes. <i>Clinical Cardiology</i> , 2019, 42, 1202-1209.	0.7	16
172	Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. <i>Heart</i> , 2015, 101, 119-125.	1.2	15
173	Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. <i>American Heart Journal</i> , 2016, 178, 1-8.	1.2	15
174	Extracellular vesicles in atrial fibrillation and stroke. <i>Thrombosis Research</i> , 2020, 193, 180-189.	0.8	15
175	The SWEDHEART secondary prevention and cardiac rehabilitation registry (SWEDHEART CR registry). <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 431-437.	1.8	15
176	Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). <i>American Journal of Cardiology</i> , 2014, 113, 669-675.	0.7	14
177	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. <i>Thrombosis Research</i> , 2016, 140, 81-88.	0.8	14
178	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. <i>American Heart Journal</i> , 2018, 198, 169-177.	1.2	14
179	Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 36-45.	1.4	14
180	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. <i>American Heart Journal</i> , 2019, 208, 65-73.	1.2	14

#	ARTICLE	IF	CITATIONS
181	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2287-2295.	1.9	14
182	Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 246-256.	0.4	13
183	Renal Function in Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 48-51.	1.6	13
184	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. <i>Europace</i> , 2020, 22, 870-877.	0.7	13
185	Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 153-163.	0.4	12
186	Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). <i>European Heart Journal</i> , 2022, 43, 2185-2195.	1.0	12
187	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 563-569.	1.0	11
188	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	1.2	11
189	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2021, 149, 27-35.	0.7	11
190	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 170, e59-e62.	0.8	10
191	Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 72, 37-43.	0.6	10
192	Lecithin: Cholesterol Acyl Transfer Rate in Plasma and its Relations to Lipoprotein Concentrations and to Kinetics of Bile Acids and Triglycerides in Hyperlipoproteinemic Subjects. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1978, 38, 103-110.	0.6	9
193	Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	9
194	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. <i>American Heart Journal</i> , 2015, 169, 531-538.	1.2	9
195	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 75-81.	1.4	9
196	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. <i>American Heart Journal</i> , 2018, 201, 25-32.	1.2	9
197	Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. <i>Platelets</i> , 2022, 33, 425-431.	1.1	9
198	Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	8

#	ARTICLE	IF	CITATIONS
199	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	8
200	Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient) Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	8
201	Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 492-501.	0.4	8
202	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. <i>Cardiovascular Research</i> , 2022, 118, 295-304.	1.8	8
203	Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome. <i>Journal of Internal Medicine</i> , 2021, 290, 392-403.	2.7	8
204	Ticagrelor in patients with heart failure after acute coronary syndromes: Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2019, 213, 57-65.	1.2	7
205	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021, 233, 92-101.	1.2	7
206	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021, 8, e001471.	0.9	7
207	Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). <i>European Heart Journal</i> , 2022, 43, 2269-2285.	1.0	7
208	Serum Neurofilament Light Chain in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 0, , .	1.6	7
209	Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation. <i>Heart</i> , 2018, 105, heartjnl-2018-314040.	1.2	6
210	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 549-559.	1.3	6
211	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	1.4	6
212	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. <i>American Heart Journal</i> , 2022, 251, 13-24.	1.2	6
213	Commentary on the OPTIDUAL trial results: how to optimise prolonged dual antiplatelet treatment and independent randomised clinical trials. <i>European Heart Journal</i> , 2016, 37, ehv499.	1.0	5
214	Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2016, 178, 176-184.	1.2	5
215	Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. <i>American Journal of Cardiology</i> , 2017, 119, 1135-1140.	0.7	5
216	Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome?. <i>Frontiers in Immunology</i> , 2017, 8, 1595.	2.2	5

#	ARTICLE	IF	CITATIONS
217	Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G372-G386.	1.6	5
218	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. <i>Atherosclerosis</i> , 2020, 293, 35-41.	0.4	5
219	Evaluation of the Age, Biomarkers, and Clinical Historyâ€“Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020, 3, e2015943.	2.8	5
220	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. <i>American Heart Journal</i> , 2020, 225, 97-107.	1.2	5
221	Cardiovascular Medicine in Sweden. <i>Circulation</i> , 2020, 141, 1124-1126.	1.6	5
222	Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events. <i>Diabetologia</i> , 2022, 65, 101-112.	2.9	5
223	No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial. <i>International Journal of Cardiology</i> , 2014, 176, 300-302.	0.8	4
224	Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. <i>Open Heart</i> , 2017, 4, e000557.	0.9	4
225	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet) Tj ETQq1 1 0.784314 rgBT /Overl	1.2	4
226	Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATElet inhibition and patient Outcomes (PLATO) study. <i>Platelets</i> , 2019, 30, 579-588.	1.1	4
227	Effects of apixaban compared with warfarin as gain in event-free time â€“ a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1311-1319.	0.8	4
228	The ABC risk score for patients with atrial fibrillation â€“ Authors' reply. <i>Lancet, The</i> , 2016, 388, 1980-1981.	6.3	3
229	Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. <i>Journal of Internal Medicine</i> , 2020, 288, 248-259.	2.7	3
230	Do we need to reconsider how we design and conduct randomised controlled trials?. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, , .	1.8	3
231	Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease. <i>PLoS ONE</i> , 2018, 13, e0204352.	1.1	2
232	Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATElet inhibition and patients Outcomes (PLATO) trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 336-349.	0.4	2
233	Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with nonâ€“valvular atrial fibrillation from the REâ€“LY trial: reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 502-504.	1.9	1
234	Response to Letter Regarding Article, â€“Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Tj ETQq0 0 0 rgBT /Overl	1.0	1

#	ARTICLE	IF	CITATIONS
235	Response to Letter Regarding Article, "Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation". <i>Circulation</i> , 2014, 129, e21-2.	1.6	1
236	Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 155-163.	0.4	1
237	Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 427-429.	1.8	1
238	P4797 Novel prognostic biomarkers identified by proximity extension assay are associated with major bleeding in patients with atrial fibrillation on oral anticoagulation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2018, 39, .	1.0	1
239	Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. <i>American Journal of Cardiology</i> , 2020, 125, 1280-1283.	0.7	1
240	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. <i>PLoS ONE</i> , 2020, 15, e0226259.	1.1	1
241	Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial. <i>European Heart Journal</i> , 2013, 34, 4536-4536.	1.0	0
242	Reduction in recurrent ischemic events with vorapaxar: results from TRACER. <i>European Heart Journal</i> , 2013, 34, P4842-P4842.	1.0	0
243	Response to Letter Regarding Article, "Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin". <i>Circulation</i> , 2014, 130, e95.	1.6	0
244	Unreliable Observations from a Confounded Analysis of a Skewed Database. <i>American Journal of Medicine</i> , 2017, 130, e355-e356.	0.6	0
245	P3626 Serial IL-6 levels and risk of death in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2017, 38, .	1.0	0
246	P625 Screening multiple biomarkers for associations with major coronary events. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
247	P976 Elevated biomarkers are associated with increased risk of death and heart failure hospitalization in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
248	P6249 Screening multiple biomarkers for associations with acute ischemic stroke in patients with stable coronary heart disease. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
249	2170 Screening multiple biomarkers for associations with cardiovascular death in patients with stable coronary heart disease. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
250	P4752 Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE. <i>European Heart Journal</i> , 2019, 40, .	1.0	0
251	P4747 Impact of different estimates of renal function on cardiovascular mortality and major bleeding in patients with atrial fibrillation on oral anticoagulation. <i>European Heart Journal</i> , 2019, 40, .	1.0	0
252	Natriuretic peptides and incident atrial fibrillation. <i>American Heart Journal</i> , 2021, 241, 120.	1.2	0

#	ARTICLE	IF	CITATIONS
253	Temporal changes of biomarkers in myocardial infarction patients with non-obstructive compared to obstructive coronary arteries. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
254	Associations between psychosocial burden and prognostic biomarkers in patients with stable coronary heart disease â€” a STABILITY substudy. <i>European Heart Journal</i> , 2020, 41, .	1.0	0